Celltrion USA has signed an agreement with the pharmacy benefit manager Express Scripts that will place the company’s subcutaneous formulation of infliximab on the Express Scripts National Preferred Formulary. While Express Scripts handles health plans for more than 100 million Americans, the PBM gave the biosimilar Preferred Brand Access that will reach 21.9 million insured customers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?